IV
Invion Limited
IVIXF · OTC
$0.00 -95.12% (-$0.04)
Market Cap $4.03M
P/E Ratio -
Div. Yield -
ROE 74.08%
Bulios Fair Price
$0
100.0% downside
Current Price
$0.0018
Undervalued Fair Value Overvalued
According to Bulios Fair Price, IVIXF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
50 /100
Fair P/S 15.14x
P/B 1.09x
P/E N/A
Growth
0 /100
Declining Rev. growth 54.00%
Book val. growth 33.03%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 347.68%
Net margin 1,464.23%
Op. margin 1,472.22%
Quality
1 /100
Poor ROIC 82.47%
ROE 74.08%
ROA 68.97%
Debt
46 /100
Moderate Debt/Equity 0.29x
Current ratio 0.24x
Int. coverage -16.33x
Stability
19 /100
Unstable Beta 0.40x
EPS volatility 151.33%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about IVIXF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Thian Chew
Employees
4
Headquarters
Melbourne